ANNUAL REPORT FY2024 29 Relationship between the remuneration policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entities financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the pre-clinical phase of drug development. 1 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the key management personnel. 2 Ian Dixon share-based compensation derived from (i) 5,999,400 performance shares granted on 16 January 2020, refer to note 9 in the accompanying financial statements for further details. (ii) 600,000 share options granted on 19 November 2020. Vesting occurred over a three year period and was completed on 19 November 2023. 3 Gisela Mautner share-based compensation derived from 1,800,000 share options granted on 3 October 2023. 600,000 options vest on the first, second and third anniversary of the grant date subject to continuous employment. 4 James Bonnar share-based compensation derived from 600,000 share options granted on 25 November 2019. The options vest over a five year period and will be completed on 25 November 2024. 2024 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees Bonus Other Superannuation Options and performance shares1 $ $ $ $ $ $ Non-Executive Directors John Moore 129,053 - - - - 129,053 Rüdiger Weseloh 49,636 - - - - 49,636 Marcus Frampton 54,599 - - - - 54,599 Christopher Cox 54,599 - - - - 54,599 Ian Dixon2 59,676 - - - 108,291 167,967 Gisela Mautner3 44,718 - - 4,898 7,417 57,033 Executive Employees James Bonnar (CEO)4 303,737 - 8,098 27,500 14,950 354,285 Total 696,018 - 8,098 32,398 130,658 867,172
RkJQdWJsaXNoZXIy MjE2NDg3